Spread the Word

Help us spread the word about the benefits of treatment for anxiety and mood disorders, OCD, and PTSD — for children and teens, women, men, and all those suffering from related illnesses.

Please tweet, post on Facebook, or add the links to your own website — whatever works to get the word out that you are not alone and help is here!

Identification of Neural Predictors of Response to Cognitive Behavioral Therapy in Depression and Anxiety

Eligibility Criteria

18 to 25 years old
Suffering from depression
18 to 55 years old
Suffering from an anxiety disorder


Exclusion Criteria

Volunteers may not have metal in their body.


This study is testing to see what behavior and brain function can tell us about treatment success in depression using cognitive-behavioral therapy, a standard psychotherapy treatment for depressive disorders.
The study purpose is to evaluate what brain function can tell us about treatment success in anxiety disorders.

Time commitment is about 33 hours over 22 visits.

Volunteers will participate in the following:

Enhancing Panic and Smoking Reduction with D-Cycloserine

Eligibility Criteria
  • Male and female patients ages 18 to 65 capable of providing informed consent
  • Willing and able to provide informed consent, attend all study visits and comply with the protocol
  • Daily smoker for at least one year
  • Currently smoke an average of at least 10 cigarettes per day
  • Report a motivation to quit smoking in the next month of at least 5 on a 10-point scale
  • Evidence of panic attack within the past year and endorsement of smoking as an emotion regulation strategy (i.e., score at least a 78 on the SAEQ).
Exclusion Criteria
  • Subjects who do not use smoking as an emotion-regulation strategy 
  • Current diagnosis of a psychotic, eating, developmental, or bipolar disorder
  • Significant suicide risk as determined by structured interview
  • Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months)  
  • Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 6 months
  • Current use of isoniazid or ethionamide compounds
  • A history of significant medical condition and/or be deemed as currently unhealthy in the context of a complete physical examination
  • Limited mental competency and the inability to give informed, voluntary, written consent to participate
  • Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt
  • Concurrent psychotherapy initiated within three months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of anxiety or mood disorder other than general supportive therapy initiated at least 3 months prior to the study
  • Use of other tobacco products
  • Plans to move outside of the immediate area in the next 6 months
  • Insufficient command of the English language



The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. Individuals will receive 7 weeks of panic- and smoking-reduction treatment (PSRT) and one pill of d-cycloserine (DCS) or one pill placebo one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).